AU599572B2 - Lymphokine production and purification - Google Patents

Lymphokine production and purification

Info

Publication number
AU599572B2
AU599572B2 AU45456/85A AU4545685A AU599572B2 AU 599572 B2 AU599572 B2 AU 599572B2 AU 45456/85 A AU45456/85 A AU 45456/85A AU 4545685 A AU4545685 A AU 4545685A AU 599572 B2 AU599572 B2 AU 599572B2
Authority
AU
Australia
Prior art keywords
csf
protein
cdna
activity
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired, expires
Application number
AU45456/85A
Other languages
English (en)
Other versions
AU4545685A (en
Inventor
Steven C. Clark
Randal J. Kaufman
Elizabeth A. Wang
Gordon G. Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27417446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU599572(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of AU4545685A publication Critical patent/AU4545685A/en
Application granted granted Critical
Publication of AU599572B2 publication Critical patent/AU599572B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request to Amend Deed and Register Assignors: SANDOZ AG
Adjusted expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Detergent Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Debugging And Monitoring (AREA)
  • Fats And Perfumes (AREA)
AU45456/85A 1984-07-06 1985-07-04 Lymphokine production and purification Expired AU599572B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US62834284A 1984-07-06 1984-07-06
US628342 1984-07-06
US65274284A 1984-09-19 1984-09-19
US65244784A 1984-09-19 1984-09-19
US652742 1984-09-19
US652447 1984-09-19

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU40090/89A Division AU628069B2 (en) 1984-07-06 1989-08-21 Lymphokine production and purification
AU54976/90A Division AU644359B2 (en) 1984-07-06 1990-05-14 Lymphokine production and purification

Publications (2)

Publication Number Publication Date
AU4545685A AU4545685A (en) 1986-02-10
AU599572B2 true AU599572B2 (en) 1990-07-26

Family

ID=27417446

Family Applications (3)

Application Number Title Priority Date Filing Date
AU45456/85A Expired AU599572B2 (en) 1984-07-06 1985-07-04 Lymphokine production and purification
AU40090/89A Expired AU628069B2 (en) 1984-07-06 1989-08-21 Lymphokine production and purification
AU54976/90A Expired AU644359B2 (en) 1984-07-06 1990-05-14 Lymphokine production and purification

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU40090/89A Expired AU628069B2 (en) 1984-07-06 1989-08-21 Lymphokine production and purification
AU54976/90A Expired AU644359B2 (en) 1984-07-06 1990-05-14 Lymphokine production and purification

Country Status (28)

Country Link
EP (2) EP0337359B1 (enExample)
JP (4) JP2540509B2 (enExample)
KR (1) KR910001809B1 (enExample)
AT (2) ATE172494T1 (enExample)
AU (3) AU599572B2 (enExample)
CA (2) CA1341618C (enExample)
CY (1) CY1629A (enExample)
DE (3) DE188479T1 (enExample)
DK (2) DK168709B1 (enExample)
ES (1) ES8701226A1 (enExample)
FI (1) FI108796B (enExample)
GR (1) GR851643B (enExample)
HK (1) HK111594A (enExample)
HU (1) HU208711B (enExample)
IE (2) IE60819B1 (enExample)
IL (2) IL75725A (enExample)
LU (1) LU88337I2 (enExample)
MY (1) MY102902A (enExample)
NL (1) NL930089I2 (enExample)
NO (4) NO179455C (enExample)
NZ (2) NZ228031A (enExample)
PL (1) PL153139B1 (enExample)
PT (1) PT80776B (enExample)
SA (1) SA94150015A (enExample)
SG (1) SG108991G (enExample)
SK (1) SK505985A3 (enExample)
UA (1) UA39161C2 (enExample)
WO (1) WO1986000639A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU608741B2 (en) * 1984-11-20 1991-04-18 Schering Biotech Corporation cDNA clones coding for polypeptides exhibiting human granulocyte macrophage and eosinophil cellular growth factor activity

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
ZA856108B (en) * 1984-10-29 1986-10-29 Immunex Corp Cloning of human granulocyte-macrophage colony simulating factor gene
WO1986004587A1 (en) * 1985-02-05 1986-08-14 Cetus Corporation Purification of native colony stimulating factor-1
EP0220520B1 (en) * 1985-09-30 1991-09-18 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor
JPS63502795A (ja) * 1985-10-03 1988-10-20 バイオジェン インコーポレイテッド 顆粒球‐マクロファージコロニー刺激因子‐様ポリペプチド、ｄｎａ配列、組換えｄｎａ分子並びに微生物細胞中でヒト顆粒球−マクロファ−ジコロニ−刺激因子−様ポリペプチドを高収量で生産する方法
CA1295567C (en) * 1988-07-25 1992-02-11 Lawrence T. Malek Expression system for the secretion of bioactive human granulocyte, macrophage-colony stimulating factor (gm-csf) and other heterologous proteins from streptomyces
US5298603A (en) * 1985-12-21 1994-03-29 Hoechst Aktiengesellschaft GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
GR871029B (en) 1986-07-14 1987-11-02 Genetics Inst Novel osteoinductive factors
US5162111A (en) * 1986-07-30 1992-11-10 Grabstein Kenneth H Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
JPH01500483A (ja) * 1986-08-11 1989-02-23 シタス　コーポレイション Ｇ‐ｃｓｆ及びそのミューテインの発現
GB8624899D0 (en) * 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
EP0276846A3 (en) * 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
JP2521094B2 (ja) * 1987-04-28 1996-07-31 アムジェン、インコーポレーテッド ヒト顆粒球マクロファ―ジコロニ―刺激因子をコ―ドする合成ｄｎａ、そのｄｎａを含むプラスミド、およびそのｄｎａで形質転換された大腸菌
ATE121134T1 (de) * 1987-06-25 1995-04-15 Immunex Corp Rinder granulocyt-makrophagenkolonie stimulierender faktor.
US5391706A (en) * 1987-07-16 1995-02-21 Schering Plough Corporation Purification of GM-CSF
ES2034239T3 (es) * 1987-07-16 1993-04-01 Schering Corporation Purificacion de gm-csf.
CA1335717C (en) * 1987-07-17 1995-05-30 Takashi Yokota Human granulocyte-macrophage colony stimulating factor and muteins thereof
AU626530B2 (en) * 1987-07-17 1992-08-06 Schering Biotech Corporation Human granulocyte-macrophage colony stimulating factor and muteins thereof
WO1989001038A1 (en) * 1987-07-24 1989-02-09 Cetus Corporation PRODUCTION OF BIOLOGICALLY ACTIVE FORMS OF CSF USING A BACULOVIRUS (AcNPV)-INSECT CELL EXPRESSION SYSTEM
EP0347057A1 (en) * 1988-05-31 1989-12-20 Schering Biotech Corporation Method of treating myeloid leukemias
AU618283B2 (en) * 1988-10-10 1991-12-19 Instituto Nazionale Per Lo Studio E La Cura Dei Tumori The use of GM-CSF in the treatment of a patient requiring high-dose chemo- or radiotherapy for cancer
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
JPH0322973A (ja) * 1989-01-19 1991-01-31 Wan Shen-Yuan ヒトヘパトーム細胞系によるコロニー形成促進因子（ＣＳＦｓ）の構成性産生
MY105946A (en) * 1989-07-14 1995-02-28 Schering Corp Antagonists of gm-csf derived from the carboxyl terminus.
DE69326829D1 (de) 1992-02-28 1999-11-25 Univ Texas Verwendung einer therapeutischen ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON VERBRENNUNGEN
US6004807A (en) * 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
US6361976B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production
US7091319B1 (en) 1992-11-24 2006-08-15 Bauer S Christopher IL-3 variant hematopoiesis fusion protein
US6413509B1 (en) 1992-11-24 2002-07-02 S. Christopher Bauer Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors
US6361977B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Methods of using multivariant IL-3 hematopoiesis fusion protein
US6153183A (en) * 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US6403076B1 (en) 1992-11-24 2002-06-11 S. Christopher Bauer Compositions for increasing hematopoiesis with interleukin-3 mutants
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5772992A (en) * 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
JP3681069B2 (ja) 1993-05-12 2005-08-10 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー Ｂｍｐ−１１組成物
ATE210182T1 (de) * 1993-06-30 2001-12-15 Lucky Ltd Modifizierte-granulocyte-makrophage-kolonie- stimulierender-faktor-gen und seine expression in hefe
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US6027919A (en) 1993-12-07 2000-02-22 Genetics Institute, Inc. BMP-12 and BMP-13 proteins and DNA encoding them
WO1995016035A2 (en) 1993-12-07 1995-06-15 Genetics Institute, Inc. Bmp-12, bmp-13 and tendon-inducing compositions thereof
US5599536A (en) * 1993-12-13 1997-02-04 Sandoz Ltd. Method for suppressing the acute phase response in a patient receiving IL-6 therapy
US5578301A (en) * 1993-12-14 1996-11-26 Sandoz Ltd. Method for using GM-CSF to reduce the acute phase response in a patient being administered IL-6 therapy
US6165748A (en) 1997-07-11 2000-12-26 Genetics Institute, Inc. Frazzled nucleotide sequences and expression products
US6676937B1 (en) 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
EP1150666B1 (en) * 1999-02-12 2009-10-28 Washington University Gm-csf for the treatment of crohn's disease
CA2386408A1 (en) 1999-10-15 2001-04-26 Genetics Institute, Inc. Formulations of hyaluronic acid for delivery of osteogenic proteins
WO2001042511A2 (en) * 1999-12-10 2001-06-14 Whitehead Institute For Biomedical Research Ibd-related polymorphisms
US6869762B1 (en) 1999-12-10 2005-03-22 Whitehead Institute For Biomedical Research Crohn's disease-related polymorphisms
US6689599B1 (en) 2000-10-20 2004-02-10 Genetics Institute, Llc Aggrecanase molecules
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7226587B2 (en) 2001-06-01 2007-06-05 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
WO2003012038A2 (en) 2001-07-27 2003-02-13 Wyeth Aggrecanase molecules
PL371525A1 (en) 2002-01-31 2005-06-27 Wyeth Aggrecanase molecules
CA2475329A1 (en) 2002-02-05 2003-08-14 Katy E. Georgiadis Truncated aggrecanase molecules
EP1525307A2 (en) 2002-07-29 2005-04-27 Wyeth Modified adamts4 molecules and method of use thereof
WO2025109150A1 (en) 2023-11-24 2025-05-30 Ludwig-Maximilians-Universität München, In Vertretung Des Freistaates Bayern The combination of gm-csf and inhibition of ccl22-ccr4 signaling in the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2092159A (en) * 1980-12-31 1982-08-11 Hayashibara Biochem Lab Process for the production of human colony stimulating factor
US4428632A (en) * 1979-08-10 1984-01-31 Thomas & Betts Corporation Coaxial cable transition connector
AU4008485A (en) * 1984-03-21 1985-09-26 Research Corporation Technologies, Inc. Recombinant DNA molecules

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom
JPH0751511B2 (ja) * 1982-03-15 1995-06-05 味の素株式会社 インターロイキン２を含有してなる癌治療剤
ZA856108B (en) * 1984-10-29 1986-10-29 Immunex Corp Cloning of human granulocyte-macrophage colony simulating factor gene
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4428632A (en) * 1979-08-10 1984-01-31 Thomas & Betts Corporation Coaxial cable transition connector
GB2092159A (en) * 1980-12-31 1982-08-11 Hayashibara Biochem Lab Process for the production of human colony stimulating factor
AU4008485A (en) * 1984-03-21 1985-09-26 Research Corporation Technologies, Inc. Recombinant DNA molecules

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU608741B2 (en) * 1984-11-20 1991-04-18 Schering Biotech Corporation cDNA clones coding for polypeptides exhibiting human granulocyte macrophage and eosinophil cellular growth factor activity

Also Published As

Publication number Publication date
DE3584089D1 (de) 1991-10-17
DK172679B1 (da) 1999-05-17
IE851695L (en) 1986-01-06
DE3588199D1 (de) 1998-11-26
SA94150015B1 (ar) 2004-09-04
PL254400A1 (en) 1986-06-17
FI860308A7 (fi) 1986-01-22
EP0188479B1 (en) 1991-09-11
LU88337I2 (fr) 1994-05-04
IL94754A0 (en) 1991-04-15
DK168709B1 (da) 1994-05-24
NO179455B (no) 1996-07-01
IL75725A0 (en) 1985-11-29
DK102886D0 (da) 1986-03-06
UA39161C2 (uk) 2001-06-15
CA1340852C (en) 1999-12-14
IL75725A (en) 1993-02-21
JPH07163351A (ja) 1995-06-27
MY102902A (en) 1993-03-31
DK59493D0 (da) 1993-05-21
ATE67244T1 (de) 1991-09-15
NO943300L (no) 1986-03-13
PT80776A (en) 1985-08-01
HU208711B (en) 1993-12-28
JP2594744B2 (ja) 1997-03-26
AU4545685A (en) 1986-02-10
SA94150015A (ar) 2005-12-03
JP2594743B2 (ja) 1997-03-26
KR860700264A (ko) 1986-08-01
DE3588199T2 (de) 1999-04-08
EP0337359A2 (en) 1989-10-18
WO1986000639A1 (en) 1986-01-30
DK59493A (da) 1993-05-21
JPH06319557A (ja) 1994-11-22
NZ212645A (en) 1990-02-26
IE930961L (en) 1986-01-06
PL153139B1 (en) 1991-03-29
NO961452D0 (no) 1996-04-12
JPS61502682A (ja) 1986-11-20
DK102886A (da) 1986-03-06
CY1629A (en) 1992-07-10
JP2594768B2 (ja) 1997-03-26
AU5497690A (en) 1990-09-13
AU644359B2 (en) 1993-12-09
FI860308A0 (fi) 1986-01-22
DE188479T1 (de) 1987-05-21
NO307348B1 (no) 2000-03-20
JPH06199897A (ja) 1994-07-19
NO179455C (no) 1996-10-09
HK111594A (en) 1994-10-21
IE60819B1 (en) 1994-08-10
NO1996016I1 (no) 1996-12-18
NO961452L (no) 1996-04-12
EP0337359A3 (en) 1990-02-07
NL930089I2 (nl) 1994-07-01
NO314941B1 (no) 2003-06-16
CA1341618C (en) 2011-07-19
HK1011709A1 (en) 1999-07-16
SK280265B6 (sk) 1999-10-08
AU628069B2 (en) 1992-09-10
HUT38675A (en) 1986-06-30
KR910001809B1 (ko) 1991-03-26
GR851643B (enExample) 1985-11-26
NL930089I1 (nl) 1993-10-01
AU4009089A (en) 1989-12-07
EP0188479A1 (en) 1986-07-30
PT80776B (pt) 1987-09-30
NO860775L (no) 1986-03-13
NO943300D0 (no) 1994-09-07
SK505985A3 (en) 1999-10-08
ES8701226A1 (es) 1986-11-16
ATE172494T1 (de) 1998-11-15
FI108796B (fi) 2002-03-28
SG108991G (en) 1992-03-20
JP2540509B2 (ja) 1996-10-02
ES544868A0 (es) 1986-11-16
NZ228031A (en) 1991-12-23
EP0337359B1 (en) 1998-10-21

Similar Documents

Publication Publication Date Title
AU599572B2 (en) Lymphokine production and purification
US5891429A (en) Recombinant human granulocyte-macrophage-colony stimulating factor (GM-CSF)
US4675285A (en) Method for identification and isolation of DNA encoding a desired protein
JPH06107692A (ja) ヘテロポリマー系蛋白質
US5942221A (en) Recombinant primate granulocyte macrophage-colony stimulating factor
JPH0657152B2 (ja) Ｃｓｆ遺伝子類
HK1011709B (en) Lymphokine production and purification
KR920002312B1 (ko) 인체 과립성 백혈구의 콜로니 자극인자
WO1986002100A1 (en) Vectors containing a gene for a protein having erythroid-potentiating activity and recombinant dna methods for producing said protein
EP0141779A1 (en) T-cell growth factor
CZ285023B6 (cs) Vektor zahrnující gen kódující bílkovinu GM-CSF primátů, hostitelská buňka, která je jím transformována, a způsob výroby bílkoviny GM-CSF primátů za jejího použití
HU204086B (en) Process for producing non-human mammal animal interferons, dna sequemces coding form them and pharmaceutical compositions comprising sand interferons